INOZYME PHARMA INC's ticker is INZY and the CUSIP is 45790W108. A total of 54 filers reported holding INOZYME PHARMA INC in Q3 2020. The put-call ratio across all filers is - and the average weighting 0.6%.
Links
Filings
- All filings
- Annual reports (10-K)
- Quarterly reports (10-Q)
- Insider transactions
- Shareholder votes
- Significant ownership
- Events
EDGAR links
External links
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,405,518 | -16.0% | 334,647 | +11.4% | 0.00% | – |
| Q2 2023 | $1,673,133 | +536.4% | 300,383 | +554.7% | 0.00% | – |
| Q1 2023 | $262,903 | +445.0% | 45,882 | -0.1% | 0.00% | – |
| Q4 2022 | $48,240 | -55.3% | 45,943 | +14.0% | 0.00% | – |
| Q3 2022 | $108,000 | -51.8% | 40,304 | -14.2% | 0.00% | – |
| Q2 2022 | $224,000 | -51.9% | 46,990 | -58.7% | 0.00% | – |
| Q1 2022 | $466,000 | -43.4% | 113,823 | -5.7% | 0.00% | – |
| Q4 2021 | $823,000 | -38.8% | 120,762 | +4.0% | 0.00% | – |
| Q3 2021 | $1,345,000 | -34.6% | 116,101 | -3.8% | 0.00% | – |
| Q2 2021 | $2,057,000 | -10.0% | 120,743 | +4.6% | 0.00% | – |
| Q1 2021 | $2,286,000 | +19.4% | 115,469 | +24.4% | 0.00% | – |
| Q4 2020 | $1,915,000 | -21.5% | 92,806 | +0.0% | 0.00% | -100.0% |
| Q3 2020 | $2,439,000 | – | 92,764 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| CHI Advisors LLC | 1,009,117 | $26,529,000 | 9.44% |
| YALE UNIVERSITY | 113,502 | $2,984,000 | 9.13% |
| Sofinnova Investments, Inc. | 2,028,308 | $53,324,000 | 3.95% |
| Novo Holdings A/S | 2,569,379 | $67,549,000 | 3.35% |
| NEA Management Company, LLC | 2,444,379 | $64,263,000 | 2.72% |
| RA Capital Management | 2,003,653 | $52,676,000 | 0.96% |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 1,150,299 | $30,241,000 | 0.74% |
| Rock Springs Capital Management LP | 879,954 | $23,134,000 | 0.59% |
| SPHERA FUNDS MANAGEMENT LTD. | 196,411 | $5,164,000 | 0.51% |
| Orbimed Advisors | 400,400 | $10,527,000 | 0.13% |